Oxandrolone
Status
No approved product. The FDA withdrew approval of oxandrolone products, including Oxandrin and the generics, for reasons of safety or effectiveness (Federal Register, 7 October 2026, document 2026-20503). The former label carried a boxed warning covering peliosis hepatis, liver cell tumours and blood lipid changes. Schedule III controlled substance.
What it is
An oral anabolic steroid with clinical history in burns and weight loss.
What published research measured
An oral anabolic steroid with a better-documented clinical record than most, including randomized trials in severe burns — where it accelerated weight restoration and improved donor site healing in paediatric and adult burn patients — and studies in HIV wasting, alcoholic hepatitis and constitutional delay of growth. It is a 17-alpha-alkylated compound, the structural feature that permits oral activity by resisting first-pass metabolism and simultaneously creates the hepatotoxicity that defines the class. The published liver findings include cholestatic jaundice, peliosis hepatis and hepatic adenoma. It suppresses HDL cholesterol markedly, more so than injected testosterone at comparable anabolic effect. Prohibited at all times under WADA class S1.1.
Source
Federal Register 2026-20503 (withdrawal of approval) · randomized trials of oxandrolone in severe burn injury Primary source
Sources
Educational use only, never medical advice. No doses.